Promising advances in the molecular landscape of NETs
Molecular genetic analyses of NETs hint at actionable therapeutic targets and potential predictive biomarkers of response to axitinib
Sinonasal cancer: whole-exome sequencing reveals potential therapeutic targets
Results from a study suggest that some existing inhibitors may benefit all subtypes of these rare malignancies, which currently lack effective treatments
New findings help guide management of appendix adenocarcinoma
Database studies in this rare cancer suggest that chemotherapy may provide survival benefit in node-positive tumours and that the KRAS G12D mutation could be a potential therapeutic target
Surgery remains the key to progression-free survival in ovarian sex cord-stromal tumours
Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer
Promising results for an FGFR 1–3 inhibitor in molecularly altered tumours
CPL304110 shows acceptable toxicity and early signs of activity in heavily pre-treated patients with advanced solid malignancies
Cancer Research
Gathering preclinical pace: cellular immunotherapy against solid tumours
Two recently published studies provide preclinical insights into ‘training’ CAR T cells that may potentially lead to more effective and less toxic immunotherapy approaches
Preliminary activity is reported with an anti-IL-8 monoclonal antibody plus nivolumab in melanoma
Combination therapy with BMS-986253 shows promise in patients progressing on checkpoint inhibitors
Combined biomarker analysis shows promise as a tissue agnostic response predictor for immunotherapy-based treatment
Pre-treatment expression of Ki-67 plus FOXC1 plus PD-L1 predicted response to neoadjuvant treatment in breast and head and neck tumours, although more work is required to determine its use in the context of immunotherapy alone
Do immune checkpoint inhibitors affect COVID-19 severity?
A joint analysis of the OnCovid and ESMO-CoCARE registries confirms the protective role of anti-SARS-CoV-2 vaccination in cancer patients treated with immunotherapy
Neoadjuvant anti-PD-L1/TGFβRII fusion protein facilitates surgery in unresectable NSCLC
Phase II study indicates that SHR-1701 alone or together with chemotherapy may be a valuable induction strategy in stage III unresectable NSCLC